trending Market Intelligence /marketintelligence/en/news-insights/trending/xpRvINLZ89JW2wJtnT0GpA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Progenics sues Novartis unit over patent filings for prostate cancer treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Progenics sues Novartis unit over patent filings for prostate cancer treatment

Progenics Pharmaceuticals Inc. filed a lawsuit in Germany against the University of Heidelberg and a unit of Novartis AG over ownership rights to a radiopharmaceutical to treat prostate cancer.

New York-based Progenics said the radiopharmaceutical PSMA-617 arose from a research collaboration between its unit Molecular Insight Pharmaceuticals and the University of Heidelberg. The university performed analyses of several drug candidates that targeted prostate-specific membrane antigen, or PSMA. Those experimental compounds were discovered by Molecular Insight and shared with the university, Progenics said.

The U.S. company said that, without its knowledge, the university exclusively licensed the patent filings to ABX GmbH, which then sublicensed it to Endocyte Inc.

Switzerland's Novartis acquired West Lafayette, Ind.-based Endocyte, a developer of cancer treatments using radioactive compounds, for $2.1 billion in December 2018.

Progenics said that in February, Endocyte filed a motion to intervene in the lawsuit filed by Molecular Insight against the university in the District Court of Mannheim in Germany.

Progenics noted that the European Patent Office accepted Molecular Insight's request and stayed the examination of the European patent applications in question.

Molecular Insight also made a filing with the U.S. Patent and Trademark Office that it was co-owner of the pending U.S. patent applications.